Late Tuesday, Vertex Pharmaceuticals gave the latest sales figures for its newest drug to treat cystic fibrosis, called Orkambi, as well as a timeline for approval of the drug it hopes will replace it in a couple years. Shares of Boston-based Vertex (Nasdaq: VRTX) were trading about flat on Thursday m..."> Late Tuesday, Vertex Pharmaceuticals gave the latest sales figures for its newest drug to treat cystic fibrosis, called Orkambi, as well as a timeline for approval of the drug it hopes will replace it in a couple years. Shares of Boston-based Vertex (Nasdaq: VRTX) were trading about flat on Thursday m..." /> Late Tuesday, Vertex Pharmaceuticals gave the latest sales figures for its newest drug to treat cystic fibrosis, called Orkambi, as well as a timeline for approval of the drug it hopes will replace it in a couple years. Shares of Boston-based Vertex (Nasdaq: VRTX) were trading about flat on Thursday m..." />

​Vertex plans to apply for approval of the drug that will replace Orkambi next year

< img src="http://media.bizj.us/view/img/2747761/0523bioflashvertex*100xx3840-3840-960-0.jpg" > Late Tuesday, Vertex Pharmaceuticals gave the latest sales figures for its newest drug to treat cystic fibrosis, called Orkambi, as well as a timeline for approval of the drug it hopes will replace it in a couple years. Shares of Boston-based Vertex (Nasdaq: VRTX) were trading about flat on Thursday morning after the company’s overall revenue and net income figures beat the bar set by analysts. Total revenue for the three months that ended in June was $432 million. That was made up mostly of sales… < div class="feedflare" > < a href="http://feeds.bizjournals.com/~ff/industry_6?a=depDJidcHts:f8ziH7FhG9c:yIl2AUoC8zA" > < img src="http://feeds.feedburner.com/~ff/industry_6?d=yIl2AUoC8zA" border="0" > < /img > < /a > < /div >
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news